In today’s recent session, 2.92 million shares of the Matinas Biopharma Holdings Inc (AMEX:MTNB) have been traded, and its beta is 1.30. Most recently the company’s share price was $1.09, and it changed around $0.25 or 29.80% from the last close, which brings the market valuation of the company to $5.54M. MTNB at last check was trading at a discount to its 52-week high of $9.60, offering almost -780.73% off that amount. The share price’s 52-week low was $0.47, which indicates that the recent value has risen by an impressive 56.88% since then.

Matinas Biopharma Holdings Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended MTNB as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight.

Matinas Biopharma Holdings Inc (AMEX:MTNB) trade information

Instantly MTNB has been showing a green trend so far today with a performance of 29.80% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.0800 on recent trading daydecreased the stock’s daily price by -0.93%. The company’s shares are currently up 113.78% year-to-date, but still up 23.90% over the last five days. On the other hand, Matinas Biopharma Holdings Inc (AMEX:MTNB) is 41.60% up in the 30-day period.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 4.58%.

MTNB Dividends

Matinas Biopharma Holdings Inc’s next quarterly earnings report is expected to be released in July.

VANGUARD GROUP INC, with 4.2869% or 9.32 million shares worth $1.48 million as of 2024-06-30, holds the second largest percentage of outstanding shares.